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OBJECTIVE
Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and
societal burdens. Long-term data determining the efficacy of individual glucose-
lowering agents on DFUs are lacking. Using existing data from the Liraglutide Effect
and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)
trial, we conducted post hoc analyses assessing the impact of liraglutide versus
placebo in peoplewith type 2 diabetes and at high risk of cardiovascular (CV) events
on the incidence of DFUs and their sequelae.
RESEARCH DESIGN AND METHODS
The LEADER trial (NCT01179048) was a randomized, double-blind, multicenter,
CV outcomes trial assessing liraglutide (1.8 mg/day) versus placebo, in addition
to standard of care, for up to 5 years. Information on DFUs was collected system-
atically during the trial, and DFU complications were assessed post hoc through
reviewing case narratives.
RESULTS
During amedian of 3.8 years’ follow-up, similar proportions of patients reported at
least one episode of DFU in the liraglutide and placebo groups (3.8% [176/4,668]
versus 4.1% [191/4,672], respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13;
P = 0.41]). Analysis of DFU-related complications demonstrated a significant re-
duction in amputations with liraglutide versus placebo (HR 0.65 [95% CI 0.45, 0.95;
P = 0.03]). However, no differences were found for foot infections, involvement of
underlying structures, or peripheral revascularization in the main analysis.
CONCLUSIONS
Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV
events in the LEADER trial did not increase the risk ofDFUevents andwas associated
with a significantly lower risk of DFU-related amputations compared with placebo.
This association, possibly due to chance, needs further investigation.
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Diabetes-related foot ulcers (DFUs) are
a common complication in people with
diabetes, estimated to affect between
9.1 million and 26.1 million people world-
wide (1). This equates to a lifetime in-
cidence of 19%–34% in patients with
diabetes (1). Long-term outcomes for
patients with DFUs are poor (1), partic-
ularly reflected in 5-year mortality rates.
For example, in patients with DFUs, the
5-year mortality rate is 44% (2) and may
be as high as 70% when patients have a
related amputation (3), a rate similar to
that for patients with colorectal cancer
(4). Alongside these high mortality rates,
the economic impact of DFU is large
(5), with the National Health Service in
England spending an estimated £972
million–£1.13 billion in 2014–2015 on
treating people with DFUs (6,7), and
$9.1–$13.2 billion is spent annually in
the U.S. (8).
Currently, the standard of care for DFU
consists of wound care, pressure off-
loading, and, when necessary, antibiot-
ics, vascular reconstruction, or surgical
debridement (1). These interventions
have some success in healing DFUs in
the short term (1,9). In the longer term,
however, there is a high risk that DFUs
will recur (1). To date, there are few
data to suggest that choice of glucose-
lowering therapies impacts on the man-
agement of DFUs or their sequelae.
It is generally agreed that good glyce-
mic control reduces the risk of compli-
cations in people with diabetes (10,11),
but its precise role in decreasing the risk
of foot complications remains unclear
due to multiple confounding factors
in most DFU trials (12). Randomized
controlled clinical trials are particularly
difficult in this field (9) due to the com-
plexity of foot ulcer pathogenesis and
the size of the study population needed
to test treatment efficacy (13). These
difficulties contribute to the lack of a
robust evidence base for adjunctive
drug therapies (14) and any benefits
they may have for patients. Indeed, a
recent cardiovascular outcomes trial
(CVOT) program of over 10,000 pa-
tients with diabetes at high risk of
cardiovascular (CV) events suggested
that one glucose-lowering agent, cana-
gliflozin, increases the risk of lower-ex-
tremity amputations (15). Little work has
been published on the effect of other
classes of glucose-lowering drugs, in-
cluding glucagon-like peptide 1 receptor
agonists (GLP-1RAs), on DFU and its out-
comes.
The Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial was a
CVOT that investigated the effect of
liraglutide versus placebo, both in addi-
tion to standard of care, on CV events
and long-term safety in patients with
type 2 diabetes and at high CV risk. In
the trial, DFU was a prespecified second-
ary end point (16). Using this existing,
extensive data set, we conducted a post
hoc analysis to assess the impact of
liraglutide, a GLP-1RA, on the incidence
ofDFUsand their sequelae inpeoplewith
type 2 diabetes.
RESEARCH DESIGN AND METHODS
In this post hoc analysis of the LEADER
data, DFUwas defined as an openwound
on the foot. Although DFU was a pre-
specified secondary end point, this was
not a primary foot ulcer trial and as such
did not include all 21 points recommen-
ded for such trials by Jeffcoate et al.
(13). For transparency and as good prac-
tice, we have included the 21-point
checklist in the Supplementary Data on-
line, comparing our methodology against
that recommended for good quality DFU
publications (Supplementary Table 1).
Study Design and Oversight
The trial design (NCT01179048) and
methods have been published previously
(16). The trial protocol, available with
the full article text, was approved by an
institutional review board or ethics com-
mittee as required by each participating
center, and all patients provided written
informed consent. Briefly, the LEADER
trial was of double-blind, placebo-
controlled design, during which patients
with type 2 diabetes and at high risk of
CV events were randomly assigned in a
1:1 ratio to liraglutide or placebo, both in
addition to standard of care. The dispo-
sition and baseline characteristics of trial
participants have been published pre-
viously (16). Information on diabetes com-
plications and risk factors for DFU was
collected at baseline. A total of 9,340
patients were randomized (full-analysis
set), 4,668 to receive liraglutide and
4,672 to placebo,with amedian follow-up
of 3.8 years. Themean percentage of time
that patients took their assigned trial
treatment was 84% in the liraglutide
group and 83% in the placebo group.
Collection of DFU Data
A selective and targeted approach to
safety data collection was applied (17),
and reporting was required only for
eventsmeeting thedefinitionof a serious
adverse event or prespecified medical
event of special interest (MESI). In the
trial, DFU was prespecified as a MESI. As
with other prespecified MESIs, informa-
tion related to DFU events (including
complications of such events) was col-
lected on a designated form.
Patients were classified as “with DFU
event” if they reported an incident DFU
or worsening of an existing DFU (i.e.,
one that was present at study entry)
during the trial. Patients “without DFU
events” did not experience a DFU as an
adverse event during the trial; however,
theymay have had aDFU at baseline that
continued throughout the trial without
worsening. Such preexisting, nonwors-
ening DFUs were not included in this
analysis.
The development of a DFU and wors-
ening of an existing DFU were captured
as adverse events and identified posttrial
based on a prespecified search using
terms from the Medical Dictionary for
Regulatory Activities on all adverse
events reported in the trial (Supplemen-
tary Table 2). In addition, a blinded re-
view conducted before database lock of
the case narratives of the events iden-
tified by this search was used to estab-
lish the nature of the DFU event and
any associated complications (i.e., am-
putations, infections, involvement of
underlying structures, or peripheral re-
vascularizations). Any events judged by
medical evaluation not to be DFUs or
that were reported as a complication of
a DFU event previously captured (i.e.,
reported as two separate events, but
during case narrative review realized to
be an event plus its complication) were
excluded from the analyses.
Unless otherwise specified, the term
“amputation” refers to all amputations
identified in this analysis. Amputations
were also further categorized (after da-
tabase lock and per International Work-
ingGroupon theDiabetic Foot guidelines
[18]) as minor, which included midtarsal
or distal amputations; major, which in-
cluded any resection proximal to mid-
tarsal level; or unknown, which were
those that could not be classified as
major or minor based on the case narra-
tives.
Statistical Methods
Summary statistics were calculated for
baseline data. The hazard ratio (HR) for
time to first DFU event and each of the
four complications (i.e., amputation
[overall, major, and minor], infection,
involvement of underlying structures,
or peripheral revascularization) was es-
timated using a Cox regression model
with treatment as a fixed factor. The
cumulative incidence was estimated us-
ing the Aalen-Johansen method, with
death as a competing risk factor. The
HR for time to all DFU events was esti-
mated using the Andersen-Gill method
for the Cox regression model on recur-
rent events with treatment as a fixed
factor.
In a separate analysis, DFU events that
occurred within 1 year of enrollment
into the study were excluded. This was
to allow for a latency effect because it
was considered that any potential pro-
tective effect of liraglutide would not be
present within the first year of treat-
ment. Thus, time to first DFU event and
DFU-related complications that occurred
1 year or more after randomization were
investigated. The HR for the time to these
events was also estimated using the Cox
regression model.
No corrections for multiple testing
were performed because all these anal-
yses were post hoc and exploratory in
nature.
RESULTS
For this post hoc analysis of the pub-
lished LEADER trial (16), 260 DFU events
in 176 patients treated with liraglutide
and 291 DFU events in 191 patients
treated with placebo were identified (Sup-
plementary Fig. 1 and Supplementary
Data).
Baseline Characteristics, Including
Risk Factors for DFU
Of the patients experiencing DFU events,
proportionally more were male, had
longer diabetes duration and poorer
glycemic control, and were administer-
ing insulin at baseline versus those with-
out DFU events (Supplementary Table
3). Although patients who experienced
DFU events during the trial appeared to
have a higher mean body weight than
those without DFU events, the mean BMI
of both groups was similar. In addition,
other risk factors for DFU (history of DFU,
neuropathy, nephropathy, retinopathy,
peripheral arterial disease, and smoking)
were present at greater proportions in
patients who experienced a DFU event
during the trial compared with those
who did not. For patients who reported
DFU events during the trial, 40.3% in
the liraglutide group and 36.1% in the
placebo group had a history of DFU at
baseline, consistent with previous data
on the recurrent nature of DFU. This
compared with 3.0% and 2.8% in the
liraglutide and placebo groups, respec-
tively, for those who did not develop
a DFU event during the trial. The corre-
sponding numbers for patients with on-
going DFU at baseline were 16.5% and
13.6%, respectively, for patients who
reported a DFU event during the trial
compared with 0.9% and 0.7%, respec-
tively, for patients without DFU events
(Supplementary Table 3).
DFU Events Over Time
A slight separation of the curves for time
to first DFU event in favor of liraglutide
appeared from month 18 and onward;
however, the HR for time to first DFU
event was 0.92 (95% CI 0.75, 1.13; P =
0.41) (Fig. 1 and Table 1), showing no
significant difference, which was the
same for time to first DFU event re-
ported from 1 year after randomiza-
tion (i.e., excluding events occurring
within the first year of trial participation
[Table 1]).
The mean number of DFU events per
100 patients was also numerically less
with liraglutide compared with placebo
from month 18 onward (Supplementary
Fig. 2). However, a HR of 0.97 (95% CI
0.82, 1.16; P = 0.76) (Table 1) for analysis
of all DFU events, including recurrent
events, indicated no significant differ-
ence between treatment arms.
Similar results were seen for the time
to first DFU event in patients with or
without a history of DFU and in patients
at high risk of DFU (i.e., no active foot
ulcer at baseline but with periph-
eral neuropathy or presence of periph-
eral artery disease or history of DFU)
(Table 1).
DFU-Related Amputations
Treatment with liraglutide resulted in
a lower proportion (25.0%; 44/176)
of patients with DFU events leading to
amputations compared with placebo
(35.1%; 67/191) (Table 2). The Cox re-
gression analysis of time to first ampu-
tation with a HR of 0.65 (95% CI 0.45,
0.95; P = 0.028) (Fig. 2A) demonstrated
a risk reduction in amputations with
liraglutide.
The treatment difference seen in am-
putations seemed driven mostly by ma-
jor amputations (liraglutide 6.3% [11/176];
placebo 11.5% [22/191]; P = 0.06) rather
than minor amputations (liraglutide 19.3%
[34/176]; placebo 24.1% [46/191]; P = 0.17)
(Table 2). However, analysis of time to
first (overall) amputations that occurred
after 1 year from randomization (i.e.,
excluding amputations within the first
year of trial participation) decreased
the risk further in favor of liraglutide
(HR 0.55, 95% CI 0.36, 0.84; P = 0.006)
(Table 2).
Figure 1—Cumulative incidence plot of time to first DFU event among all patients in the LEADER
trial. Aalen-Johansen plot, with death as a competing risk factor. This figure includes data from
the first DFU events in 176 liraglutide-treated and 191 placebo-treated patients.
Other DFU-Related Complications
For DFU-related infection and DFU in-
volving underlying structures, the cu-
mulative incidence plots appeared to
separate over time (at months 18 and 24,
respectively) in favor of liraglutide, but
the HRs of time to these events were
not significant (Fig. 2B and C). In addition,
there was no difference between treat-
ments in DFU requiring peripheral revas-
cularization (Fig. 2D).
The HR for time to first DFU-related
infection that occurred after 1 year from
randomization was 0.74 (95% CI 0.55,
0.99; P = 0.044) in favor of liraglutide
(Table 2).
CONCLUSIONS
This post hoc analysis of data from the
LEADER trial showed that the use of
liraglutide in patients with type 2 di-
abetes at high risk of CV events did
not increase the risk of a DFU event
compared with placebo. Although there
were numerically fewer DFU events with
Table 1—HRs associated with DFU events in the LEADER trial
Liraglutide Placebo HR (95% CI) P value
DFU events
Time to first DFU event, n (%)* 176 (3.8) [FAS = 4,668] 191 (4.1) [FAS = 4,672] 0.92 (0.75, 1.13) 0.41
Time to first DFU event after 1 year, n (%)† 127 (2.8) [FAS = 4,599] 149 (3.2) [FAS = 4,601] 0.85 (0.67, 1.07) 0.16
Time to all DFU events (including recurrent
events), n of events 260 291 0.97 (0.82, 1.16) 0.76
By background characteristics, n (%)
Time to first DFU event in patients with history of DFU 71 (34.1) [FAS = 208] 69 (35.2) [FAS = 196] 0.97 (0.69, 1.35) 0.84
Time to first DFU event in patients with no history of DFU 105 (2.4) [FAS = 4,460] 122 (2.7) [FAS = 4,476] 0.86 (0.66, 1.11) 0.25
Time to first DFU event in patients at high risk of DFU 101 (5.8) [FAS = 1,747] 110 (6.2) [FAS = 1,787] 0.93 (0.71, 1.22) 0.60
DFU event is defined as reporting of an incident DFU or worsening of an existing DFU. Cox regression model with treatment as a fixed factor. High risk
of DFU is defined as a patient with type 2 diabetes who at baseline did not have an active foot ulcer but had peripheral neuropathy or presence
of peripheral artery disease or history of DFU. FAS, full-analysis set. *n, number of patients with a first DFU between randomization and follow-up
dates. †n, number of patients with first foot ulcer after 1 year from randomization date and before follow-up date (i.e., excludes event occurring
within the first year of trial participation).
Table 2—Complications associated with DFU events
Liraglutide (N = 4,668)
(PYO = 17,822)
Placebo (N = 4,672)
(PYO = 17,741)
HR (95% CI) P valuen % of N
Patients with
DFU (%) E R n % of N
Patients with
DFU (%) E R
DFU events or related complications
Patients with DFU event(s) 176 3.8 100.0 260 1.46 191 4.1 100.0 291 1.64 0.92 (0.75, 1.13) 0.41
Patients with DFU event(s) +
complication of
Amputation 44 0.9 25.0 60 0.34 67 1.4 35.1 78 0.44 0.65 (0.45, 0.95) 0.03
Minor 34 0.7 19.3 45 0.25 46 1.0 24.1 50 0.28 0.74 (0.47, 1.15) 0.17
Major 11 0.2 6.3 13 0.07 22 0.5 11.5 24 0.14 0.50 (0.24, 1.02) 0.06
Unknown 1 0.0 0.6 2 0.01 4 0.1 2.1 4 0.02 d d
Infection 107 2.3 60.8 146 0.82 131 2.8 68.6 162 0.91 0.81 (0.63, 1.05) 0.11
Involvement of underlying
structures 64 1.4 36.4 86 0.48 80 1.7 41.9 98 0.55 0.80 (0.57, 1.11) 0.17





n % of N n % of N HR (95% CI) P value
Analysis of first DFU-related
complications that
occurred after 1 year
from randomization*
Amputation 32 0.70 58 1.26 0.55 (0.36, 0.84) 0.006
Infection 75 1.63 101 2.20 0.74 (0.55, 0.99) 0.044
Involvement of underlying
structures 47 1.02 67 1.46 0.70 (0.48, 1.01) 0.06
Peripheral revascularization 11 0.24 20 0.43 0.55 (0.26, 1.14) 0.11
Analyses based on review of case narratives. P values were based on an analysis of time to first event using a Cox regression model with treatment as
fixed factor. Infection is defined as presence of clinical signs of infection, including redness, warmth, pain, purulence, or discharge. Involvement of
underlying structures is defined as tendon, joint capsule, or bone. Minor amputations are defined as midtarsal or distal amputation and major
amputations as any resection proximal to midtarsal level (18). Unknown amputations are defined as those that could not be classified as
major or minor based on the case narratives. E, number of events; N, number of patients in the treatment group; n, number of patients with
an event or complication; PYO, patient-years of observation; R, event rate per 100 PYO. *Percentages of patients are of the full-analysis set (liraglutide,
N = 4,599; placebo, N = 4,601). This analysis excluded complications occurring within the first year of trial participation.
liraglutide compared with placebo, the
difference was not significantly differ-
ent. However, the HRs for time to DFUs
requiring lower-extremity amputation
were significantly lower in the liraglutide
arm than for those given placebo. Treat-
ment with liraglutide also resulted in a
risk reduction in DFU-related amputations
compared with placebo when excluding
amputations that occurred within the
first year of enrollment into the trial.
There is a need for DFU therapies with
proven benefit with the large disease
burden; social, personal, and economic
impact of DFUs (1,5,6); current limited
treatment options available (1,19); and
the high risk of DFU recurrence (1). To
date, very limited data have been pub-
lished on the effect of glucose-lowering
drugs on DFUs and associated compli-
cations. Intensive glucose control had
no impact on the risk of amputation
or development of peripheral vascular
disease compared with conventional
therapy in the UK Prospective Diabetes
Study (UKPDS) and Action in Diabetes
and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation
(ADVANCE) studies, but DFU was not
a specified end point in these trials
(11,20,21). In the Veterans Affairs Di-
abetes Trial (VADT), amputation due
to ischemic gangrene was included
within the composite primary end point,
but data related to amputation or foot
ulcers only do not appear to have been
published (22,23). For the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) study, data relating to some
types of microvascular foot compli-
cations have been published but not
amputation or foot ulcers (24). More re-
cently, results from Canagliflozin Cardio-
vascular Assessment Study (CANVAS)
and CANVAS-Renal (CANVAS-R) (studies
in which amputation data were system-
atically collected and reported) have in-
dicated that the risk for both leg and foot
amputations in canagliflozin-treated
patients is approximately double that
for placebo-treated patients (15). At this
point in time, this does not seem to
be a class effect of the sodium–glucose
cotransporter 2 inhibitors as a post hoc
analysis of the BI 10773 (Empagliflozin)
Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients
(EMPA-REG OUTCOME) trial did not
show an increase in major or minor am-
putation risk in those with preexisting
peripheral arterial disease, a group known
to be at high risk ofDFUevents (25).More
data regarding amputation on another
sodium–glucose cotransporter 2 inhibitor
(dapagliflozin) will be available when the
Dapagliflozin Effect on Cardiovascular
Events (DECLARE-TIMI 58) CVOT is pub-
lished later this year. To date, other than
antibiotics used to treat infected wounds,
only one other drug, fenofibrate, has
been suggested to reduce the risk of
amputation in patients with type 2 di-
abetes (26).
Examining the DFU data from the
LEADER trial in detail, it was apparent
that these were similar to data from
other DFU studies. Within the LEADER
trial population, the proportion of
Figure 2—Cumulative incidence plot of time to first DFU-related complication among patients treated with liraglutide vs. placebo in the LEADER
trial. A: Amputation (44 first DFU events in the liraglutide group and 67 first DFU events in the placebo group). B: Infection (107 and 131 first
DFUevents in liraglutide and placebo groups, respectively). C: Involvement of underlying structures (64 and 80 first DFUevents in liraglutide and
placebo groups, respectively). D: Peripheral revascularization (20 and 23 first DFU events in liraglutide and placebo groups, respectively).
patients who had a medical history of
DFU but did not report another (i.e.,
recurrent) DFU during the trial was very
low (placebo 2.8%, liraglutide 3.0%).
When compared with those who re-
ported a DFU event during the trial, the
proportion with a medical history of
DFU was much higher (placebo 36.1%,
liraglutide 40.3%), indicating the recur-
rent nature of DFU. These numbers agree
with those published by Armstrong et al.
(1), which showed that the recurrence
rate within 1 year of healing was 40%,
increasing to 65% within 5 years.
The important findings for DFU-
related amputations lead to the ques-
tion as to the possible mechanisms.
Well-known risk factors for DFU include
poor glycemic control, history of DFU,
smoking, and long diabetes duration
(19,27). Analysis of the baseline charac-
teristics of patients who experienced a
DFU event during the trial reflected
these risk factors. Any differences re-
ported here are likely to be directly a
result of the assigned study treatment
because the risk factors for DFU were
balanced at baseline between the two
treatment groups. Within the trial, there
was modest improvement in some of
these risk factors, such as glycemic con-
trol and weight loss, in the liraglutide
group compared with placebo (16). It is
unknown if the improvements in these
effects contributed to the reduced in-
cidence of DFU-related amputations in
the liraglutide group.
Other possible links between DFU
pathology and GLP-1RA receptor ago-
nism could be reduced inflammation
and increased angiogenesis. These have
been demonstrated in rodents with
diabetes treated intraperitoneally with
exendin-4 (28). Also, liraglutide increased
atherosclerotic plaque stability in ro-
dents, which could reduce vascular dis-
ease (29). It is possible that similar
mechanisms could be induced by liraglu-
tide in humans and are relevant here, as
inflammation is linked to DFU pathology
(27). This effectmay not be unique to the
GLP-1RA class because other incretin-
based therapies may also impact DFU
healing, as shown recently by a preclin-
ical and clinical study with saxagliptin,
a dipeptidyl peptidase 4 inhibitor (30).
Limitations and Strengths
Although we evaluated a previously un-
explored question, this was a post hoc
analysis of the LEADER trial, which was
designed to assess CV safety and not the
risk of DFU in great detail. This analysis
was exploratory in nature and did not
correct for multiple testing; therefore,
caution is needed when interpreting the
data. Also, the inclusion/exclusion crite-
ria did not mention DFU; however, the
target population was those at high risk
for CV events, which would inherently
have included patients at risk for DFU
events. DFU was a prespecified MESI,
which resulted in the systematic collec-
tion of events and associated compli-
cations. However, information on the
location of the DFU and management
of DFU (e.g., care afforded to individ-
ual patients and duration of event)
was not systematically collected, which
would have allowed events to be inves-
tigated in greater detail.
Due to the protocol and method of
safety data collection, it was not possi-
ble to analyze all amputations that oc-
curred during the trial, but only those
related toDFUevents. This is because the
underlying cause for any procedure or
surgery was reported as the adverse
event and not the procedure itself (un-
less the underlying cause was unknown).
However, as 85% of lower-extremity am-
putations are preceded by a DFU (18),
it is likely that the number of amputa-
tions not included in this analysis was
relatively small.
The checklist to assess the quality of
study reports about DFU (13) was com-
pleted for this post hoc analysis (Sup-
plementary Table 1). Although the trial
prespecifiedDFUas secondary endpoint,
it was not powered for the analyses
applied here. The low number of events
and the relatively short follow-up (me-
dian follow-up 3.8 years) may have af-
fected the potential to find further
differences between the liraglutide and
placebo arms. For example, the cumu-
lative plots for DFU events overall, DFU
events with infection, and DFU events
with involvement of underlying struc-
tures separated in favor of liraglutide
after between 18 and 24 months, but
did not reach statistical significance.
However, given that this trial recruited
those at high CV risk with baseline gly-
cated hemoglobin concentrations .7.0%
(53 mmol/mol)dand thus at high risk
of DFUdand had large sample size, it is
unlikely that a similar trial will be done
to examine foot outcomes specifically.
Although theoverall risk ofDFUevents
was similar between liraglutide and pla-
cebo, the reduced risk for DFU-associated
amputations suggests the value from
such a post hoc analysis. Furthermore,
the prespecified data collection increased
the robustness of these analyses; other
strengths include that DFU incidence was
monitored in a large population at risk for
DFU within a randomized clinical trial
population.
Summary
This post hoc analysis of data from the
LEADER trial suggests that treatment
with liraglutide in patients with type 2
diabetes and at high risk of CV events
did not increase the risk of DFU events
and was associated with a significantly
lower risk of DFU-related amputations
compared with placebo. The association
between the use of liraglutide and re-
duction in amputation in those at high
CV risk could be due to chance but merits
further investigation.
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